OIL (ASX) Anyone hungry?

Originally posted by RamboMyStepBro ↑

There must be an update coming from this new board sometime soon and they should explain why we were informed in December past by the previous Chairman that there would be Highlights.
Thought I would pull up the market update and review what the Chairman told us six months ago.
He has gone but Dr Currie was on the board then and is still there now.
I bought more shares based on this information but nothing on this update from the board has happened or been explained to shareholders why it has not.
At a minimum an update on the FDA dates which we were informed would be 'well before the end of the first half of 2018'
Dr Currie and Mr Mutton have been around for a while now and need to tell us what is going on.

Here is what we were told in December.
Market Update
December 22 2017
Highlights:

A minimum revenue of $1.95m from the sale of systems that will be delivered to Zeiss by June 2018

CE approval anticipated well within the first quarter 2018 enabling a strong sales push into Europe

FDA submission early 2018 with approval anticipated well before the end of the first half of 2018

Optiscan Imaging Limited (ASX:OIL) is pleased to provide this month’s market update following a recent visit by the Optiscan Chairman, Alan Hoffman, to the headquarters of Carl Zeiss Meditec (“CZM”) in Oberkochen Germany. This update will therefore concentrate on the CZM project.
The key points of note are as follows:
CE Approval

CZM anticipate CE approval will be following the approval of the sterility process of the sheath. This is anticipated to be well within the first quarter of 2018.

Once CE mark is approved, the CZM Convivo systems can be sold in Europe.

The CZM senior management are keen to strongly push European sales as soon as CE is approved.
FDA Approval

Following the sheath sterility regulatory approval, the complete system (incl sheath and fluorescein) will be submitted to the FDA for approval.

The CZM USA regulatory team is, in parallel, preparing the FDA submission to minimize any delay. The submission will be made early in 2018 with approval anticipated to be secured well within the first half of 2018.

CZM senior management are keen to push USA sales as soon as FDA is approved.
Future Deliveries
The revenue for Optiscan from next shipments is anticipated to be as follows:

January 2018 AUD700k*

March 2018 AUD625k*

June 2018 AUD625k*
*Note: The CZM contract provides for payment in EUR. The above revenue figures are based on expected AUD/EUR exchange rates
These figures are based on anticipated orders along with orders already received. There is upside potential in the first half of 2018 depending on the timing of CE and FDA approvals and the subsequent sales push as referred to above.
Closing Remarks
“Optiscan is proud to be associated with Zeiss – a high quality organisation operating with a strong presence on the global stage. Their facilities, organisation and people reflect an organisation with a strong reputation for delivering a quality product on a global scale. Impressive as that is, even more impressive is their drive to achieve results. Optiscan is confident of strong results in 2018 due to its collaboration with a strong business partner in Zeiss,” said Optiscan Chairman Alan Hoffman.
Mr Hoffman added “The board and management would like to take this opportunity to wish our shareholders a very Merry Christmas and a safe and Happy New Year”
Corporate Enquiries:
Alan Hoffman
Chairman - Optiscan Imaging Limited E: [email protected]

Expand

Yes but see, after this was published things blew up at the mill. I harbour a sneaking suspicion that the announcement relating to the timing of the FDA approval was significant in the relationship melt down. It may have been unintentional initially, but after that personalities took over and maybe clarification became an issue and secrecy and confidentiality prevailed because of legal issues.

Basically I think we were misinformed and I wouldn't depend on it. Having said that I think things are well advanced

No.	Vol.	Price($)
1	27533	16.0¢

No.

Vol.

Price($)

27533

16.0¢

Price($)	Vol.	No.
16.5¢	51052	3

Price($)

Vol.

No.

16.5¢

51052

No.	Vol.	Price($)
1	100000	0.040
1	23529	0.034
1	63140	0.033
1	25000	0.024
1	60000	0.021

No.

Vol.

Price($)

100000

0.040

23529

0.034

63140

0.033

25000

0.024

60000

0.021

Price($)	Vol.	No.
0.044	20000	1
0.045	93965	2
0.048	100000	1
0.049	225000	1
0.050	87172	3

Price($)

Vol.

No.

0.044

20000

0.045

93965

0.048

100000

0.049

225000

0.050

87172

(20min delay)
Last 16.0¢		Change 0.000(0.00%)		Mkt cap ! $129.4M

Open	High	Low	Value	Volume
15.5¢	16.0¢	15.5¢	$8.8K	55.75K

Anyone hungry?, page-18

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

White Cliff Minerals bags lucrative Canadian deposit at Rae Copper

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Buyers (Bids)

Sellers (Offers)

Anyone hungry?, page-18

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

White Cliff Minerals bags lucrative Canadian deposit at Rae Copper

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Buyers (Bids)

Sellers (Offers)